Status:
COMPLETED
Study Of Celecoxib In Healthy Subjects
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
40-74 years
Phase:
PHASE4
Brief Summary
A study to confirm the superiority of celecoxib 100 mg BID to loxoprofen 60 mg TID in the incidence of gastroduodenal endoscopic ulcers after 2 weeks treatment.
Eligibility Criteria
Inclusion
- Healthy Volunteers
Exclusion
- Endoscopic evidence of ulceration, erosion or active bleeding etc. in the esophagus, stomach, pylorus and/or duodenum prior to treatment endoscopy
- A history of gastrointestinal ulcer
- Any use of celecoxib, nonsteroidal anti-inflammatory drugs (including aspirin), anti-ulcer medication, antacids, systemic steroids or antibiotics within four weeks prior to the first dose of study medication
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT00994461
Start Date
November 1 2009
End Date
April 1 2010
Last Update
February 2 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Yokohama, Kanagawa, Japan
2
Pfizer Investigational Site
Minato-ku, Tokyo, Japan
3
Pfizer Investigational Site
Shinjuku-ku, Tokyo, Japan